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 Primary congenital glaucoma (PCG; OMIM 231300) is
an inherited ocular congenital anomaly of the trabecular mesh-
work and anterior chamber angle that leads to the obstruction
of aqueous outflow, increased intraocular pressure (IOP), and
optic nerve damage resulting in childhood blindness. The dis-
ease manifests in the neonatal or early infantile period with
symptoms of photophobia, epiphora, and signs of enlargement
of the globe, edema, opacification of the cornea, breaks in the
Descemet’s membrane, and others [1]. The prevalence of PCG
varies across ethnic communities and geographical boundaries,
ranging from 1 in 10,000-20,000 in the western populations
[2] to 1 in 2,500 and 1 in 1,250 in the Saudi Arabian [3] and
Gypsy populations of Slovakia [2], respectively. In the Indian
state of Andhra Pradesh, prevalence is estimated to be around
1:3,300 and accounts for 4.2% of all childhood blindness [4].
The mode of inheritance is largely autosomal recessive with
variable penetrance but rare cases of pseudodominance are
also seen in families with multiple consanguinity [1]. Three
chromosomal loci have been linked to PCG: GLC3A (2p21),
GLC3B (1p36), and GLC3C (14q24.3) [5-7]. GLC3A, harbor-
ing the human cytochrome P450 gene CYP1B1 (OMIM
601771), has been characterized [3]. More than 40 different
mutations have been identified in CYP1B1 to be causal for
PCG in different ethnic backgrounds and populations high-
lighting the allelic heterogeneity of the condition [8,9].
The involvement of CYP1B1 in other PCG populations
varies from 20% in Indonesians and Japanese to 50% among
the Brazilians and about 100% among the Saudi Arabians and
Slovakian Gypsies [8,10-12]. Also it was shown that the
Slovakian Gypsies and Saudi Arabian populations exhibited
allelic homogeneity that was largely attributed to consanguin-
ity and inbreeding [13,14]. Consanguinity and inbreeding are
also prevalent in different ethnic groups of India [15] and thus
provide an excellent opportunity to explore the role of CYP1B1
causing PCG in these populations.
Earlier we reported the involvement of CYP1B1 in 5 PCG
families from India and devised PCR-based restriction frag-
ment length polymorphism (RFLP) methods to detect these
mutations [16]. With this strategy we further screened 138 PCG
cases and found that 30.8% of these cases were positive for
one of the previously identified six mutations and that R368H
happened to be the most prevalent mutation in the Indian popu-
lation [17]. In order to understand the spectrum of CYP1B1
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mutations causing PCG in Indian populations, we screened
CYP1B1 in 64 new and unrelated cases from different ethnic
backgrounds.
METHODS
Clinical examination and selection of cases:  The study pro-
tocols adhered to the guidelines of the Declaration of Helsinki.
After approval of the Institutional Review Board, 64 consecu-
tively diagnosed PCG cases from different ethnic backgrounds,
presenting at the L. V. Prasad Eye Institute from January 2001
to June 2003 were recruited. All patients underwent slit lamp
biomicroscopy, applanation tonometry, and gonioscopy (where
corneal clarity permitted). General anesthesia (Savoflorane)
was used in the younger age groups and where required. The
inclusion criteria were increased corneal diameter (>12.0 mm)
along with raised intraocular pressure (>21 mm Hg) and/or
presence of Haab’s striae, or optic disc changes (where ex-
amination was possible). Symptoms of epiphora, photopho-
bia, and rupture in the Descemet’s membrane were the cor-
roborating factors. The age of onset ranged from 0-1 years.
Clinical diagnosis was confirmed independently by two glau-
coma surgeons (AKM and RT) with expertise in congenital
glaucoma. Seventeen cases had a positive family history of
the disease, while the rest were sporadic. Parental consanguin-
ity was seen in 55% of these cases. One hundred ethnically
matched normal individuals without any ocular disorders
served as controls. Peripheral blood samples were collected
from the probands, their relatives, and controls by venipunc-
ture with prior informed consent.
Screening of CYP1B1 gene: DNA was extracted from the
leukocytes following standard protocols [18]. The entire cod-
ing regions of CYP1B1 were amplified using three sets of pre-
designed oligonucleotide primers with PCR conditions as de-
scribed earlier [16]. The 485 bp upstream region (2,748 bp to
3,233 bp) flanking four important regions for maximum pro-
moter activity was screened using a set of forward (5'-AGC
GGC CGG GGC AGG TTG TAC C-3') and reverse (5'-ATT
GGG ATG GGG ACG GAG AA-3') primers. PCR was per-
formed with 25 µl reaction mixtures containing 50 ng of ge-
nomic DNA, 1X PCR buffer (containing 100 mM Tris-HCl,
500 mM KCl and 0.8% Nonidet P40) with MgCl2, 200 mM of
dNTPs, 0.5 µM of each primer, 10% DMSO, and 1 unit of
Taq DNA polymerase (MBI Fermentas, Vilnius, Lithuania).
The amplification conditions were an initial denaturation at
95 °C for 3 min followed by 30 cycles of denaturation, an-
nealing and extensions at 95 °C (30 s), 62 °C (30 s), and 72 °C
(45 s), respectively with a final extension at 72 °C for 7 min.
The amplicons were purified using spin-columns (Sigma-
Aldrich, St. Louis, MO) and subjected to bi-directional se-
quencing using BigDye terminator (version 3.1) chemistry
according to the manufacturers protocol (Applied Biosystems,
Foster city, CA). Sequencing was performed on an automated
DNA sequencer (ABI 3100) and the data were analyzed with
the SEQUENCING ANALYSIS software (Both from Applied
Biosystems, Foster City, CA).
RESULTS
Identification of 7 novel mutations:  Direct sequencing revealed
16 different mutations in 24 unrelated cases, of which 7 were
novel. These included two frameshift mutations leading to
deletions of 23 bp (g.3905del23bp, Figure 1) and 2 bp (g.7900-
7901delCG, Figure 2) in the second and third exons, respec-
©2004 Molecular VisionMolecular Vision 2004; 10:696-702 <http://www.molvis.org/molvis/v10/a84>
Figure 1. A novel mutation leading to
the deletion of amino acid sequence
HVGQRLLR in CYP1B1.  Electro-
pherogram of the sense strand of ge-
nomic DNA showing a homozygous
deletion at g.3905-3927del23bp result-
ing in the inframe deletion of the 8
amino acids HVGQRLLR (B) com-
pared to the sequence derived from the
control (A).
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tively. The deletions resulted in the creation of premature stop
codons, thereby truncating the ORFs. The 23 bp deletion be-
gins at nucleotide 3,905 and ends at 3,927 (reference sequence
U56438) resulting in an inframe deletion of 8 amino acids i.e.
the sequence his-val-gly-gln-arg-leu-leu-arg (or
HVGQRLLR). Four novel missense mutations viz.
g.4148G>C (A115P), g.4200T>G (M132R), g.4236A>C
(Q144P), and g.4520A>C (S239R) were noted in the second
exon, and one g.8234G>A (G466D) in the third exon (Figure
3). Except for S239R (that was present in 2 different cases),
all other novel mutations were present in single cases only.
All these mutations segregated with the affected phenotype
and were absent in 200 normal chromosomes and their resi-
dues were mostly conserved across different species (Figure
4). Five of these mutations also resulted in the loss of restric-
tion sites thereby facilitating their screening in the population
(Table 1).
Other mutations in CYP1B1: Apart from these novel
changes, 9 other mutations were noted in 16 PCG cases, which
has already been reported in other ethnic groups
[11,14,16,17,19-22]. These included a frameshift mutation
leading to a 10 bp homozygous duplication g.8037-
8046dupTCATGCCACC in PCG110 and 7 missense changes
viz. L77P, R368H, R390H, R390C, P437L, E229K, and P193L
(Table 1). The R368H was the most frequent mutant allele (7/
25 cases) and also exhibited compound heterozygosity in as-
sociation with R390C and G61E alleles in probands belong-
ing to 2 non-consanguineous families. Three cases were het-
erozygous for the mutant alleles Q144P, R368H, and E229K.
However no variation was observed in the non-coding regions
or promoter of CYP1B1 in the heterozygous cases indicating
the involvement of some other causal gene that is yet
uncharacterized.
We also observed six benign intragenic variants at -13T/
C, R48G, A119S, V432L, D449D, and N453S that were re-
ported in other populations [19]. But there was no common
haplotype based on these single nucleotide polymorphisms
that segregated with all these mutations, unlike in other popu-
lations [11,13,14].
DISCUSSION
 Mutations in CYP1B1 have been associated with PCG with
varying frequencies across different ethnic communities and
geographical boundaries [8,10-12]. Populations with higher
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Figure 2. A novel deletion in
CYP1B1.  Electropherogram of
the sense strand of genomic DNA
showing a homozygous deletion
at g.7900-7901delCG (B) com-
pared to the sequence derived
from normal control (A).
Figure 3. A novel mutation in the signature se-
quence of CYP1B1.  Electropherogram of the
sense strand of the genomic DNA showing a ho-
mozygous transition at g.8234G->A resulting in a
G466D mutation (B) compared to the sequence
derived from the normal control (A). Glycine
forms a highly conserved part in the signature se-
quence of the gene (C).
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rate of inbreeding and consanguinity exhibit a higher frequency
of CYP1B1 mutations in PCG as opposed to ethnically di-
verse populations [12,13]. Screening a cohort of 64 consecu-
tive PCG cases from different geographical locales of India
revealed 37.50% (24/64 cases) mutations in CYP1B1. Of these
24 cases, consanguinity was seen in 16 cases and 3 of them
had a positive family history. Homozygosity of the mutant
allele was seen in 29.68% (19/64) and compound heterozy-
gosity in 3.12% (2/64) of the cases, respectively. However
there was no association of any mutation with the gender or
ethnicity of the individual.
The homozygous deletion at g.3905-3927delHVGQRLLR
in the proband PCG050 (Figure 1) resulted in the truncation
of the CYP1B1 protein to 51 aa, thereby missing 492 aa from
the C-terminus. This occurred at the end of the membrane
domain resulting in the elimination of all-important domains
of CYP1B1 protein in exon II. It also led to the abolition of a
restriction site for BbvCI. The other homozygous deletion at
g.7900-7901delCG in the proband PCG081 (Figure 2) resulted
in the truncation of CYP1B1 protein at 373 aa in the “J” helix
(350 aa-363 aa). The resulting protein therefore lacked the
“K” and “L” helices along with the “heme binding” regions
and also caused the loss of a restriction site for TaqI in exon
III. The PCG050 and PCG 081 probands presented at 7 years
and 2 months, respectively. Although surgical intervention
could lower their IOPs, visual recovery was poor in both of
them (Table 2).
Among the missense mutations, the homozygous substi-
tution at g.4148G->C resulted in a change from alanine to pro-
line (A115P) in exon II in the proband PCG008. This muta-
tion occurred in the N-terminal region of the cytosolic do-
main between the “B” (100 aa-107 aa) and “C” (141 aa-151
aa) helices causing a loss of a restriction site for BsgI. The
importance of proline residues in the proline-rich region of
microsomal cytochrome P450s has demonstrated the presence
of typical carbon monoxide difference spectrum in the wild
type P450 that was lacking in the mutant protein (due to the
substitution of alanine by proline) [23]. Taking this into con-
sideration, we suspect that the A115P mutation might also cause
a conformational change of the protein due to an extra proline
residue. This patient underwent a surgical intervention at 6
days after birth and had a better IOP control and visual recov-
ery (Table 2).
Another homozygous substitution at g.4200T->G caused
a change from methionine to arginine (M132R) in exon II in
the proband and his younger brother in PCG122 family. This
mutation was located between the “B” and “C” helices of the
CYP1B1 protein that resulted in a loss of a restriction site for
NlaIII. A comparative modeling of CYP1B1 using CYP2C5
as a template showed the possibility of hydrogen bond forma-
tion with main chain amide in this residue (Unpublished). Thus
this mutation could disrupt this hydrogen bond formation and
affect the final conformation of the protein. Both the siblings
in PCG122 family presented with raised IOP and visual acu-
ity of “fixing and following of light” but the elder brother had
to undergo Transcleralcyclophotocoagulation (TSCPC) due to
his advanced nature of the glaucoma and late age of interven-
tion (6 years).
A homozygous substitution at g.8234G->A resulted in the
replacement of glycine by aspartic acid (G466D) in proband
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      P450 species               A115P     M132R      Q144P       S239R     G466D
      --------------------    ----------   ------   ---------   ---------   -----
      Human CYP2A7             QAEEFSGRG   GYGVAF   RAKQLLRFA   TSTGQLYEM   SIGKR
      Human CYP2B6             KAEAFSGRG   GYGVIF   RWKVLRRFS   SVFGQLFEL   SLGKR
      Human CYP2F1             QGEEFSGRG   GNGIAF   RWKVLRQFS   SPWGELYDI   SAGRR
      Human CYP2E1             YKDEFSGRG   DRGIIF   AWKDIRRFS   TPWLQLYNN   STGKR
      Rat CYP1B1               QGGVFADRP   GRSLAF   RWKERRRAA   A--GSLVDV   SVGKR
      Scup CYP1B1              QGGVFADRP   GRSLAF   RWKERRRAA   A--GSLVDV   SVGKR
      Human CYP1B1             QGSAFADRP   GRSMAF   HWKVQRRAA   A--GSLVDV   SVGKR
      Plaice CYP1B             QGTDFAGRP   GDSLAF   WWKVHRRVA   A--GSIVDV   SLGKR
      Scup CYP1C2              HSTEFAGRP   GRSMTF   QWKMHRKIA   A--GSLVDV   SSGKR
      Monkey CYP1A1            QGDDFKGRP   GWSMSF   VWAARRRLA   S--GNPADF   GLGKR
      Human CYP1A1             QGDDFKGRP   GWSMSF   VWAARRRLA   S--GNPADF   GMGKR
      Golden hamster CYP1A1    QGDDFKGRP   GKSMIF   VWAARRRLA   S--GYPPDF   GLGKR
      Rabbit CYP1A2            QGDDFKGRP   GWSMIF   VWAARRRLA   S--GSPADF   GLGKR
      Dog CYP1A2               QGDDFKGRP   SWSMSF   VWAAGRRLA   S--GNPLDF   GMGKR
      Human CYP1A2             QGDDFKGRP   GWSLTF   VWAARRRLA   S--GNPLDF   GMGKR
      Guinea pig CYP1A2        QSDDFKGRP   GWSMIF   VWAARRRLA   S--GNPVDF   GLGKR
      Golden hamster CYP1A2    QGDDFKGRP   GKSMTF   VWAARRRLA   S--GNAVDF   GLGKR
      Chicken CYPA4            QAEDFMGRP   GHSLAF   AWKARRKLA   A--GNPADF   GLGKR
      Scup CYP1A1              QGDXFAGRP   GKSLAF   VWRARRKLA   S--GNPADF   GMGKR
      Trout CYP1A1             QGEDFAGRS   GKSLAF   VWRARRKLA   S--GNPADF   GMGKR
      Oyster toadfish CYP1A1   QGEDFSGRP   GKSLAF   VWRARRKLA   T--GNLADF   GLGKR
      Human CYP17              KGKDFSGRP   NRKGIA   HWQLHRRLA   K--DSLVDL   GAGPR
Figure 4. Conservation of residues across cytochrome P450 families around the region of missense mutations.  Multiple sequence alignment
of Cytochrome P450 families showing the conservation of wild type amino acids (marked in red) for the 5 novel missense mutations. The
human CYP1B1 protein is marked in blue.
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PCG009 (Figure 3). This residue is highly conserved across
all cytochrome P450s and is a part of the “signature sequence”
(NH2-FXX GXX XCX G-COOH) that is present in all heme
binding cytochromes at the C-terminus of the protein (Figure
4). The cysteine residue in this sequence acts as the fifth ligand
to heme. The other conserved residues and hydrophobic amino
acids viz. phenylalanine and glycine next to the axial ligand
(cysteine) are very important for the apoprotein to hold and/or
incorporate the heme plane at the active site of P450 [24]. In
spite of early intervention, visual prognosis was poor in this
proband (Table 2).
Another homozygous mutation at g.4520A->C resulted
in the replacement of serine by arginine (S239R) between the
“F” (219 aa-234 aa) and “G” (259 aa-281 aa) helices of
CYP1B1 protein. This was the only mutation that was ob-
served independently in the probands of 2 families (PCG021,
PCG147). Both the probands with S239R mutation had ad-
vanced glaucoma at presentation. Although their IOPs could
be controlled by surgical intervention, their visual acuity did
not improve significantly (Table 2).
A heterozygous change g.4236A->C resulted in the sub-
stitution of glutamine by proline (Q144P) in exon II in the
proband PCG086. Although this residue is conserved only in
humans (Figure 4), it was not seen in either of his parents or
controls. This de novo mutation lay in the “C” helix (141 aa-
151 aa) of the protein and caused a loss of a restriction site for
MspA1I. The insertion of proline in the middle of the “C”
helix could induce a turn and further affect the final confor-
mation of protein. This proband was intervened early and had
a better prognosis with normal IOP and improved visual acu-
ity (Table 2).
Among all the mutations, R368H was again found to be
the most frequent change (29.16%), similar to our previous
study that reported it to be the most predominant CYP1B1
allele in the Indian population [17]. This mutation has rarely
been reported from the other ethnic groups. So far only a few
PCG families (from Saudi Arabia and Brazil) were found to
have this mutation at a very low frequency [11,14]. Early in-
tervention in 5 probands with the homozygous and heterozy-
gous R368H mutant allele had a relatively better visual prog-
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TABLE 1. DISTRIBUTION OF 16 CYP1B1 MUTATIONS IN 24 PCG PATIENTS IN INDIAN AND WORLD POPULATIONS
Serial                                                Restriction   Cases
number      Nucleotide change       Exon   Mutation      site       (n=24)     Populations
------   ------------------------   ----   --------   -----------   -----   -----------------
   1     g.3905-3927del23 bp        II                - Bbv CI        1     India
   2     g.3987 G>A                 II     G61E       + Taq I         1*    Saudi Arabia [14]
                                                                            India
   3     g.4035 T>C                 II     L77P                       1     Saudi Arabia [14]
                                                                            India
   4     g.4148 G>C                 II     A115P      - Bsg I         1     India
   5     g.4200 T>G                 II     M132R      - Nla III       1     India
   6     g.4236 A>C                 II     Q144P      - Msp A1I       1     India
   7     g.4383 C>T                 II     P193L      + Eco 801I      1     India [16]
   8     g.4491 G>A                 II     E229K      - Eam 1140I     1     Lebanon [20]
                                                                            France [21]
                                                                            India [16]
   9     g.4520 A>C                 II     S239R                      2     India
  10     g.7900-7901delCG           III               - Taq I         1     India
  11     g.7940 G>A                 III    R368H      - Taa I         7     Saudi Arabia [14]
                                                                            Brazil [11]
                                                                            USA [22]
                                                                            India [16]
  12     g.8005 C>T                 III    R390C      + Hinf I        2     India [17]
  13     g.8006 G>A                 III    R390H      - Cfo I         3*    Pakistan [19]
                                                                            India
  14     g.8147 C>T                 III    P437L                      1     Turkey [19]
                                                                            Brazil [11]
                                                                            India
  15     g.8234 G>A                 III    G466D                      1     India
  16     g.8037-8046dupTCATGCCACC   III               + Nla III       1     USA [22]
                                                                            UK [19]
                                                                            Turkey [19]
                                                                            Brazil [11]
                                                                            Germany [20]
                                                                            France [21]
                                                                            India
The details of 16 CYP1B1 mutations reported, along with their location in the gene, which exon, the type of change, and the restriction
enzymes used for screening those mutations by RFLP. The “Cases” column indicates the number of cases in which the corresponding mutation
was present out of a total 24 cases with mutations in the present study. The “Populations” column indicates the detection of a particular
mutation in various global populations; references are cited for those noted reported herein. The minus sign (-) in the “Restriction site” column
indicates the abolition of the restriction site and the plus sign (+) indicates the creation of the restriction site. In the “Cases” column, the
asterisk indicates cases which include one compound heterozygous with R368H.
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nosis, as opposed to probands who were compound heterozy-
gous for R368H in association with G61E and R390H mutant
alleles and intervened at later ages (Table 2). The codon 390
in CYP1B1 happens to be a mutation hot spot in various popu-
lations [14,19,21]. However visual outcomes were relatively
better in probands with the R390C mutation who underwent
early surgical interventions than those with the R390H muta-
tion, who were intervened late and also developed phthisis
bulbi in one of their eyes (Table 2). Thus a variable prognosis
was noted in probands with CYP1B1 mutations. Although our
clinical experience suggests a better visual prognosis for early
intervention in PCG [25], our current findings may suggest a
larger role of the type of mutation, leading to structural and
functional alteration of the CYP1B1 protein. However, func-
tional studies of these mutations and analysis on a larger se-
ries would throw more light in understanding the protein al-
terations leading to the severity of phenotype in PCG.
The involvement of CYP1B1 in PCG was found to be
lower (37.50%) in our population than those reported in Saudi
Arabian (95.0%) and Slovakian Gypsy populations (100%).
This could be due to a higher rate of inbreeding and allelic
homogeneity in these populations [12,13]. Relatively lower
frequencies of CYP1B1 mutations have been observed in Bra-
zilian (50%) and south east Asian populations such as Japa-
nese (20%) and Indonesians (about 34%) [8,10,11]. Interest-
ingly, none of the CYP1B1 mutations in Japanese and Indone-
sian populations were found in Indian PCG populations. This
could be attributed to the genetic heterogeneity and ethnic di-
versities in these populations. As there was no association of
any specific intragenic haplotypes to these mutations, it could
imply multiple independent origins of these mutations that
warrants further investigations. In summary, this study pro-
vides a mutation spectrum of CYP1B1 causing PCG in Indian
populations that has implications in devising molecular diag-
nostics for rapid screening in predisposed families [22] and
would aid early intervention.
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PCG110    g.8037-8046dupTCATGCCACC     H          C       birth      2 year     16    26    FFL       FFL
Details of clinical features of the 24 probands with CYP1B1 mutations indicating their genotype, age at onset, and diagnosis along with their
visual outcomes following surgical intervention with respect to IOP and visual acuity at the last follow-up. The “Alleles” column indicates
whether the patient was homozygous (H), heterozygous (h), or compound heterozygous (CH). Marriages were classified as consanguineous
(C) or non-consanguineous (NC). The final Intraocular pressure (IOP) is given except when it was not available due to a phthisical eye. The
final visual acuity is given as a snellen measurement when possible; otherwise, it is listed as hand movements (HM), counts fingers (CF), light
perception with projection (LPP), fixes and follows light (FFL), and no light perception (NLP).
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